Safety and Reactogenicity of the Inactivated Poliomyelitis Vaccine (PoliorixTM) in Korea (2006-2012)
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: As per the requirement of Korean Food and Drug Administration, this post-marketing surveillance was conducted in Korea to evaluate the safety and reactogenicity of PoliorixTM following its introduction in 2006. Methods: In this open, multicenter study, the vaccine was administered as per the current practice of Korean doctors and in reference to the guidebook by the Korean Pediatric Society and as indicated in the Korean label which was as follows - for primary vaccination three doses were given to infants at ages 2, 4 and 6 months whereas, for the booster dose a single dose was given to children aged 4-6 years. Safety data during this six year surveillance was collected using diary cards which were distributed to the parents to record adverse events. Results: A total of 639 subjects were enrolled into the study. Of these, 617 subjects and 22 subjects received the vaccine as a primary and booster dose, respectively. At least one unsolicited symptom was reported in 11.4% (73/639) of the subjects during the 7-day follow-up period; upper respiratory tract infection (2.5%;16/639) was the most frequently reported unsolicited symptom. One subject reported at least one unsolicited symptom (gastroenteritis) of grade 3 intensity within the 31- day post-vaccination period. Approximately 1.7% (11/639) of subjects reported 13 serious adverse events (SAEs). All SAEs were resolved by the end of the study. Conclusion: In Korea, primary and booster vaccination with PoliorixTM was well-tolerated in healthy subjects when administered according to the prescribing information as part of routine clinical practice.
Abstract
Objective: As per the requirement of Korean Food and Drug Administration, this post-marketing surveillance was conducted in Korea to evaluate the safety and reactogenicity of PoliorixTM following its introduction in 2006. Methods: In this open, multicenter study, the vaccine was administered as per the current practice of Korean doctors and in reference to the guidebook by the Korean Pediatric Society and as indicated in the Korean label which was as follows - for primary vaccination three doses were given to infants at ages 2, 4 and 6 months whereas, for the booster dose a single dose was given to children aged 4-6 years. Safety data during this six year surveillance was collected using diary cards which were distributed to the parents to record adverse events. Results: A total of 639 subjects were enrolled into the study. Of these, 617 subjects and 22 subjects received the vaccine as a primary and booster dose, respectively. At least one unsolicited symptom was reported in 11.4% (73/639) of the subjects during the 7-day follow-up period; upper respiratory tract infection (2.5%;16/639) was the most frequently reported unsolicited symptom. One subject reported at least one unsolicited symptom (gastroenteritis) of grade 3 intensity within the 31- day post-vaccination period. Approximately 1.7% (11/639) of subjects reported 13 serious adverse events (SAEs). All SAEs were resolved by the end of the study. Conclusion: In Korea, primary and booster vaccination with PoliorixTM was well-tolerated in healthy subjects when administered according to the prescribing information as part of routine clinical practice.
참고문헌 (14)
- "Polio this week: data and monitoring"[URL]
- "Poliomyelitis: Fact Sheet Number 114" (2011)[URL]
- Minor P, "Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication", Vaccine, 27, pp.2649~2652 (2009)
- Dutta A, "Epidemiology of poliomyelitis-options and update", Vaccine, 26, pp.5767~5773 (2008)
- Centers for Disease Control and Prevention, "Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination", MMWR Morb Mortal Wkly Rep, 58, pp.829~830 (2009)
- "Immunization profile: Republic of Korea" (2012)[URL]
- The Korean Pediatric Society, "Poliovirus vaccine, In Immunization Guideline", pp.1~4 (2008), The Korean Pediatric Society
- "Poliorix™: WHO Package Insert" (2010)[URL]
- Epidemiology and prevention of vaccine-preventable disease, "Advisory Committee on Immunization Program", Korea Center for Disease Control and Prevention, 123~137 (2005)
- Sun Jun Kim, "Vaccine-associated Paralytic Poliomyelitis: A Case Report of Flaccid Monoparesis after Oral Polio Vaccine", Journal of Korean Medical Science, 22(2), pp.362~364 (2007), 대한의학회
- Tebbens RJD, "Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication", Risk Anal, 26, pp.1471~1505 (2006)
- Bonnet MC, "World wide experience with inactivated poliovirus vaccine", Vaccine, 26, pp.4978~4983 (2008)
- Li Y, "Immunogenicity and safety of an inactivated poliovirus vaccine in Chinese infants", Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID) (2011), The Melbourne
- Lee SY, "Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the republic of Korea", Vaccine, 29, pp.1551~1557 (2011)